BIOCON
Biocon
Each stock's 10,000-path forecast, rendered as light.
Biocon (BIOCON) Stock Analysis & Case Study
Is BIOCON a good buy? The data-driven verdict.
Biocon (BIOCON) trades at ₹421,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Biocon (BIOCON) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 175.0× earnings, ROE of 1.4%, a 57% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
BIOCON fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is BIOCON overvalued? BIOCON P/E vs its Pharma
BIOCON's P/E of 175.0× sits above the Pharma peer median of 30.0×, so on earnings it screens richer than peers, while its 0.12% dividend yield is below the peer median of 0.51%.
BIOCON share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of BIOCON history (10%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| BIOCON 2027 | ₹294 | ₹437 | ₹648 | +5% |
| BIOCON 2028 | ₹260 | ₹455 | ₹805 | +10% |
| BIOCON 2029 | ₹240 | ₹483 | ₹957 | +16% |
| BIOCON 2030 | ₹227 | ₹510 | ₹1,129 | +23% |
| BIOCON 2031 | ₹218 | ₹529 | ₹1,307 | +27% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability BIOCON goes up, or doubles?
The bull case for BIOCON
- Biocon is part of the nifty100 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹957.
The bear case & risks
- A rich 175.0× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 1.4%, capital efficiency trails higher-quality peers.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹240.
BIOCON volatility & expected range, how bumpy is the ride?
Over the last 2.0 years BIOCON compounded at 10%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹294–₹648, the honest backbone behind any single price target.
BIOCON price forecast, the full 60-month probability fan
BIOCON price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds BIOCON hits common targets within the simulated horizon?
Full multi-horizon detail on the BIOCON price target & forecast page.
BIOCON Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. BIOCON scores 4/9,mixed financial health.
BIOCON MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy BIOCON with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 29.0% | 3.4× |
| Zerodha | 24.7% | 4.0× |
| DhanCHEAPEST | 24.0% | 4.2× |
Compare every broker on the BIOCON MTF page.
BIOCON vs peers,Pharma comparison
About Biocon: sector, index & market-cap context
Biocon (BIOCON) is a mid-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹68,224 Cr. See more Nifty 100 stocks.
How the BIOCON Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Biocon's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
BIOCON analysis, FAQs
Is Biocon (BIOCON) a good buy?
On the numbers, Biocon (BIOCON) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 175.0× earnings, ROE of 1.4%, a 57% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is BIOCON overvalued or undervalued?
BIOCON trades at 175.0× earnings versus a peer median of 30.0×, so it screens richer than its Pharma peers.
What is the BIOCON share price target for 2031?
BIOCON's probability-weighted 2031 median target is ₹529, with an 80% range of ₹218–₹1,307 (10,000-path Monte-Carlo).
What is the probability BIOCON doubles in 5 years?
The modelled probability of BIOCON reaching ₹831 (2×) within 5 years is 26%.
What is the bull case for BIOCON?
Biocon is part of the nifty100 universe with live, tracked fundamentals on Downstox.
What are the risks in BIOCON?
A rich 175.0× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 1.4%, capital efficiency trails higher-quality peers.